RU2004116319A - Система регулируемой экспрессии нуклеиновых кислот - Google Patents
Система регулируемой экспрессии нуклеиновых кислот Download PDFInfo
- Publication number
- RU2004116319A RU2004116319A RU2004116319/13A RU2004116319A RU2004116319A RU 2004116319 A RU2004116319 A RU 2004116319A RU 2004116319/13 A RU2004116319/13 A RU 2004116319/13A RU 2004116319 A RU2004116319 A RU 2004116319A RU 2004116319 A RU2004116319 A RU 2004116319A
- Authority
- RU
- Russia
- Prior art keywords
- product
- nucleic acid
- cell
- protein
- acid construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (20)
1. Упаковывающая клетка, содержащая первую, вторую и третью конструкции нуклеиновых кислот, которые регулируют экспрессию одного или нескольких вирусных генных продуктов, необходимых для упаковки вирусного вектора, где
указанная первая конструкция нуклеиновой кислоты содержит регулируемый тетрациклином промотор/оператор, который регулирует экспрессию кодируемого первого продукта;
указанный первый продукт способен регулировать экспрессию второго продукта, кодируемого указанной второй конструкцией нуклеиновой кислоты; и
указанный второй продукт способен регулировать экспрессию указанного вирусного генного продукта, кодируемого последовательностью, присутствующей на указанной третьей конструкции нуклеиновой кислоты.
2. Клетка по п.1, где указанным первым продуктом является трансактиватор регулируемого тетрациклином промотора/оператора или гибридный белок, включающий указанный трансактиватор.
3. Клетка по п.1 или 2, где указанная вторая конструкция нуклеиновой кислоты содержит регулируемый тетрациклином промотор/оператор.
4. Клетка по п.1 или 2, где указанным вторым продуктом является белок rev.
5. Клетка по п.1 или 2, где указанная третья конструкция содержит промотор, происходящий от ретровирусного 5’LTR.
6. Клетка по п.1 или 2, где указанным первым продуктом является белок tat или химерный белок, включающий белок tat.
7. Клетка по п.1 или 2, которая является стабильно трансфицированной указанными конструкциями нуклеиновых кислот.
8. Клетка по п.1 или 2, которая, кроме того, содержит вирусный вектор, реплицирующийся в зависимости от условий и которая упаковывает указанный вектор.
9. Клетка по п.8, где указанный вектор происходит от ВИЧ-1.
10. Клетка по п.1, где указанным вирусным генным продуктом является белок вирусной оболочки или G-белок.
11. Клетка по п.10, которая, кроме того, содержит дополнительную конструкцию нуклеиновой кислоты, кодирующую ретровирусные белки gag и pol.
12. Клетка по п.10, где указанным вторым продуктом является белок rev.
13. Клетка по п.10, где указанным вирусным генным продуктом является G-белок.
14. Клетка по п.10, которая, кроме того, содержит условно реплицирующийся вирусный вектор и которая упаковывает указанный вектор.
15. Упаковывающая клетка, содержащая первую, вторую и третью конструкции нуклеиновых кислот, которые регулируют экспрессию одного или нескольких белков вирусной оболочки или G-белков, где
указанная первая конструкция нуклеиновой кислоты способна экспрессировать кодируемый первый продукт;
указанный первый продукт способен регулировать экспрессию второго продукта, кодируемого указанной второй конструкцией нуклеиновой кислоты; и
указанный второй продукт способен регулировать экспрессию указанного белка вирусной оболочки или G-белка, кодируемого последовательностью, присутствующей на указанной третьей конструкции нуклеиновой кислоты.
16. Клетка по п.15, которая, кроме того, содержит дополнительную конструкцию нуклеиновой кислоты, кодирующую ретровирусные белки gag и pol.
17. Клетка по п.15, где указанным вирусным генным продуктом является G-белок.
18. Клетка по п.17, где указанным G-белком является G-белок вируса VSV или Мокола.
19. Способ упаковки вирусного вектора, предусматривающий культивирование клетки по п.9 в условиях, при которых указанная первая конструкция нуклеиновой кислоты экспрессирует указанный первый продукт.
20. Способ упаковки вирусного вектора, предусматривающий культивирование клетки по п.14 в условиях, при которых указанная первая конструкция нуклеиновой кислоты экспрессирует указанный первый продукт.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/020,472 | 2001-10-30 | ||
| US10/020,472 US6835568B2 (en) | 2001-10-30 | 2001-10-30 | Regulated nucleic acid expression system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004116319A true RU2004116319A (ru) | 2005-03-27 |
Family
ID=21798805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116319/13A RU2004116319A (ru) | 2001-10-30 | 2002-10-30 | Система регулируемой экспрессии нуклеиновых кислот |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6835568B2 (ru) |
| EP (1) | EP1446488A4 (ru) |
| JP (1) | JP2005512573A (ru) |
| KR (1) | KR100984268B1 (ru) |
| CN (1) | CN100591769C (ru) |
| AU (1) | AU2002365090B2 (ru) |
| BR (1) | BR0213964A (ru) |
| CA (1) | CA2464268C (ru) |
| CZ (1) | CZ2004546A3 (ru) |
| IL (2) | IL161495A0 (ru) |
| MX (1) | MXPA04003969A (ru) |
| NO (1) | NO20041763L (ru) |
| NZ (1) | NZ533132A (ru) |
| RU (1) | RU2004116319A (ru) |
| WO (1) | WO2003054210A2 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297536B2 (en) * | 2003-01-23 | 2007-11-20 | Wisconsin Alumni Research Foundation | Inducible protein expression system |
| US20090123494A1 (en) * | 2007-07-31 | 2009-05-14 | William Staplin | Momlv-based pseudovirion packaging cell line |
| WO2009120947A1 (en) * | 2008-03-28 | 2009-10-01 | Virxsys Corporation | Lentivirus-based immunogenic vectors |
| AU2010316996A1 (en) * | 2009-11-05 | 2012-06-14 | Proyecto De Biomedicina Cima, S.L. | Regulated expression systems |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| RU2752498C2 (ru) | 2015-11-24 | 2021-07-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Стабильные клеточные линии для продуцирования ретровирусов |
| FR3044017B1 (fr) | 2015-11-24 | 2019-05-03 | Glaxosmithkline Intellectual Property Development Limited | Procede de transfection transitoire pour la production retrovirale |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2140380T5 (es) | 1990-03-21 | 2005-03-16 | Geneart Gmbh | Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. |
| US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
| US5888767A (en) * | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| WO2000065076A2 (en) | 1999-04-26 | 2000-11-02 | K.U. Leuven Research & Development | Synthetic gene for expressing active retroviral protein in eukaryotes |
-
2001
- 2001-10-30 US US10/020,472 patent/US6835568B2/en not_active Expired - Fee Related
-
2002
- 2002-10-30 KR KR1020047006464A patent/KR100984268B1/ko not_active IP Right Cessation
- 2002-10-30 AU AU2002365090A patent/AU2002365090B2/en not_active Ceased
- 2002-10-30 CA CA2464268A patent/CA2464268C/en not_active Expired - Fee Related
- 2002-10-30 MX MXPA04003969A patent/MXPA04003969A/es active IP Right Grant
- 2002-10-30 EP EP20020802938 patent/EP1446488A4/en not_active Withdrawn
- 2002-10-30 BR BRPI0213964-2A patent/BR0213964A/pt not_active Application Discontinuation
- 2002-10-30 IL IL16149502A patent/IL161495A0/xx unknown
- 2002-10-30 NZ NZ533132A patent/NZ533132A/en not_active IP Right Cessation
- 2002-10-30 WO PCT/US2002/034932 patent/WO2003054210A2/en not_active Application Discontinuation
- 2002-10-30 CZ CZ2004546A patent/CZ2004546A3/cs unknown
- 2002-10-30 RU RU2004116319/13A patent/RU2004116319A/ru not_active Application Discontinuation
- 2002-10-30 CN CN02821442A patent/CN100591769C/zh not_active Expired - Fee Related
- 2002-10-30 JP JP2003554911A patent/JP2005512573A/ja active Pending
-
2004
- 2004-04-19 IL IL161495A patent/IL161495A/en not_active IP Right Cessation
- 2004-04-29 NO NO20041763A patent/NO20041763L/no not_active Application Discontinuation
- 2004-12-13 US US11/011,264 patent/US8043611B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003054210A2 (en) | 2003-07-03 |
| EP1446488A2 (en) | 2004-08-18 |
| EP1446488A4 (en) | 2004-12-22 |
| US20060121579A1 (en) | 2006-06-08 |
| AU2002365090A1 (en) | 2003-07-09 |
| NZ533132A (en) | 2008-04-30 |
| MXPA04003969A (es) | 2004-07-08 |
| IL161495A (en) | 2009-06-15 |
| WO2003054210B1 (en) | 2004-02-26 |
| AU2002365090B2 (en) | 2007-12-20 |
| KR100984268B1 (ko) | 2010-09-30 |
| KR20040066799A (ko) | 2004-07-27 |
| IL161495A0 (en) | 2004-09-27 |
| CN1578837A (zh) | 2005-02-09 |
| WO2003054210A3 (en) | 2003-12-24 |
| US20030087419A1 (en) | 2003-05-08 |
| US8043611B2 (en) | 2011-10-25 |
| US6835568B2 (en) | 2004-12-28 |
| JP2005512573A (ja) | 2005-05-12 |
| CA2464268C (en) | 2012-03-20 |
| NO20041763L (no) | 2004-04-29 |
| CZ2004546A3 (cs) | 2004-10-13 |
| CA2464268A1 (en) | 2003-07-03 |
| CN100591769C (zh) | 2010-02-24 |
| BR0213964A (pt) | 2006-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10829785B2 (en) | Nucleic acid application primers | |
| Lavillette et al. | A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes | |
| Kafri et al. | A packaging cell line for lentivirus vectors | |
| Craven et al. | Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras | |
| Ansorge et al. | Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures | |
| US6218181B1 (en) | Retroviral packaging cell line | |
| EP3420091B1 (en) | Nucleic acid constructs for producing retroviral vectors | |
| JP2018506983A5 (ru) | ||
| Kim et al. | HTLV-1 and-2 envelope SU subdomains and critical determinants in receptor binding | |
| CA2164835A1 (en) | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells | |
| NO995382L (no) | Lentivirus baserte genoverfoeringsvektorer | |
| Sparacio et al. | Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors | |
| RU2004116319A (ru) | Система регулируемой экспрессии нуклеиновых кислот | |
| Blaise et al. | Identification of an envelope protein from the FRD family of human endogenous retroviruses (HERV-FRD) conferring infectivity and functional conservation among simians | |
| Hernandez et al. | Mutational analysis of the candidate internal fusion peptide of the avian leukosis and sarcoma virus subgroup A envelope glycoprotein | |
| Zhao et al. | Functional domains in the retroviral transmembrane protein | |
| CA2557882A1 (en) | Defective packaging non-oncoviral vectors based on mpmv and hiv | |
| EP3854879A1 (en) | Method for enhancing lentivirus vector production | |
| Broussau et al. | Packaging cells for lentiviral vectors generated using the cumate and coumermycin gene induction systems and nanowell single-cell cloning | |
| Merten et al. | Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles | |
| WO2001044458A3 (en) | Bovine immunodeficiency virus (biv) based vectors | |
| Bachrach et al. | Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein | |
| Fischer et al. | A retroviral packaging cell line for pseudotype vectors based on glioma‐infiltrating progenitor cells | |
| O'Reilly et al. | G541R within the 4070A TM protein regulates fusion in murine leukemia viruses | |
| US20240167055A1 (en) | Compositions and methods for producing and characterizing viral vector producer cells for cell and gene therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091001 |